
Sermorelin
Sermorelin acetate (GHRH 1-29)
Sermorelin is a synthetic 29-amino acid peptide that mimics the biologically active portion of growth hormone releasing hormone (GHRH). Originally FDA-approved in 1997 as Geref® for treating children with growth hormone deficiency, it stimulates the pituitary gland to produce natural growth hormone in physiological pulsatile patterns. Unlike direct growth hormone injections, sermorelin works with the body's feedback mechanisms to prevent overdose and maintain natural GH rhythms.
Clinical Benefits
Mechanism of Action
Sermorelin functions as a synthetic analog of the first 29 amino acids of endogenous growth hormone releasing hormone (GHRH). It binds specifically to GHRH receptors (GHRHR) on somatotroph cells of the anterior pituitary gland, activating adenylyl cyclase and increasing intracellular cAMP levels. This cascade stimulates transcription of the growth hormone gene and promotes GH synthesis and secretion in natural pulsatile patterns. The physiological regulation via somatostatin feedback prevents excessive GH release and maintains the integrity of the growth hormone neuroendocrine axis, unlike exogenous recombinant GH administration.
Proven Results
Medical Disclaimer
Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.